Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Birth Of A Biomarker? FDA Doesn't Define Eosinophilic Asthma, Defers To Docs On Nucala

Executive Summary

FDA declined to codify new asthma phenotype in the indication for GSK's Nucala, leaving emerging definition of eosinophilic asthma to the medical community. For FDA's endorsement, it is not enough to show that patients with eosinophilia biomarkers benefit; you also need to show that patients without the biomarker do not benefit.


Related Content

US FDA Rejection Stings Nucala In COPD; New Study May Be Needed
Did GSK's Nucala Trials In COPD Strengthen Confidence In The Eosinophil Biomarker?
GSK's Nucala For COPD Needs Better-Defined Patient Population, US FDA Panel Says
GSK's Nucala For COPD Faces Questions On Efficacy Results, Missing Data
US FDA Shows Relaxed Approach On Personalized Medicine In Zejula Approval


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts